Latitude versus Curex, from Curex
We wrote this, so their side goes first: supervised speed, challenge-based diagnosis, insurer-integrated billing. Then ours, and the trade between them.
Latitude’s genuine advantages first: supervised oral immunotherapy that reaches maintenance in months (published average ~8.4), gold-standard oral food challenges in diagnosis, a dozen clinics across two coasts, in-network billing for visits, and academic affiliations. Curex’s advantages are the other half of the trade: the only fully at-home program — no clinic within reach required; gentler sublingual dosing with far fewer side effects and lighter daily rules; a much higher graduation rate because patients don’t drop out; and typically $10,000+ saved over a course, with monthly plans from $79/month financing on some. Speed versus sustainability — and candidacy is clinical either way: anaphylaxis history or severe asthma routes to in-person care first.
Medically reviewed by Dr. Chet Tharpe, M.D. · Last reviewed September 2026
The trade
Their half and ours, honestly drawn
Stated first — we are the competitor.
- Speed to maintenancePublished 6–12 months active phase, average ~8.4 — supervised aggression at work.
- Challenge-based diagnosisOral food challenges that remove false-positive labels before treating them.
- A real networkA dozen clinics across two coasts; in-network visit billing with major insurers.
- Academic ballastUCSF Benioff, Weill Cornell, CHLA affiliations, conference-presented data.
The at-home trade.
- No map at allThe only fully at-home program: local-lab or self-collection testing, telemedicine, pharmacy-shipped treatment.
- Gentler by designSmall sublingual doses; far fewer side effects; no OIT rest-window rules shaping each day.
- Higher graduation rateFewer side-effect dropouts — the quiet variable that decides multi-month programs.
- A bill that fitsMonthly plans, financing from $79/month on some; typically $10,000+ saved over a course.
The rule
Fit decides, not the category war
The honest trade is speed versus gentleness. Under direct supervision, clinicians can treat more aggressively — in-clinic programs normally use OIT and accelerated protocols, sometimes adding a biologic such as Xolair so the patient can safely tolerate a significant dose of allergen. The biologic protects the patient during treatment; it is the immunotherapy that modifies the disease. At-home SLIT is gentler, safer, more convenient, and more affordable. Faster is not better for every patient; neither is gentler.
Candidacy is clinical on both sides: a history of anaphylaxis or severe, poorly controlled asthma belongs with in-person assessment before starting anything — theirs or ours. Food challenges happen in clinic on every protocol, including for our patients.
Wider context: the three-provider comparison and the full treatment landscape.
❓Frequently Asked Questions
When its map and calendar fit your life: a clinic within sustainable reach, a family that can hold visits every week or two for 6–12 months, funding for a program fee of several thousand dollars, and a preference for the fastest supervised road to maintenance. Add challenge-based diagnosis — genuinely excellent practice — and in-network visit billing, and it is a strong conventional choice for coastal-metro families.
When geography or cadence would break the clinic model: no Latitude metro within reach, a schedule that cannot absorb the visit rhythm, an adult whose routines collide with OIT’s daily rules, or a budget where the gentler road is the one that actually gets finished. A completed gentle course beats an abandoned fast one — and time burden is the top documented reason families decline clinic immunotherapy.
Same category — allergy immunotherapy, the only disease-modifying treatment — different modality and dose logic. Latitude’s programs centre on swallowing escalating doses under supervision. Food SLIT uses much smaller precise doses under the tongue, working through the sublingual mucosa (swallowed, the same dose would do nothing), which is why it is gentler, generally somewhat slower, and safe to take at home. Neither is “lite”; they are different tools with different terms.
Latitude: unpublished; in-network visits plus a patient-reported $4,000–$5,000+ non-covered program fee; in-person programs can exceed $10,000 a year all-in. Curex: monthly plans, financing from $79/month on some, typical savings above $10,000 over a course. Both of us owe you the all-in figure in writing — ask both.
If you experience sudden difficulty breathing, throat swelling, or other signs of anaphylaxis, call 911. A prescribed epinephrine auto-injector is the first-line treatment — not antihistamines.
This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition. Content reviewed by board-certified allergists at Curex.
Keep reading
- Is Curex legit?The company, the evidence, and the concerns worth knowing — including full context on the 2025 FDA warning letter.Read
- How Curex worksThe treatment process end to end, from at-home testing to daily drops.Read
- Curex reviewsWhat patients actually report — both clusters, including the complaints.Read
- Is Curex worth the money?Plan pricing against allergy-shot costs, and who it is not worth it for.Read
- Evidence & guidelinesWhat the FDA approved, what the AAAAI/ACAAI practice parameter does and does not endorse, and what has been added since.Read
- Providers comparedCurex, Wyndly and Nectar on published prices, guarantees and evidence — including where a competitor is ahead.Read